Herceptin Research Today is a free monthly online journal that collates and summarizes the latest research about Herceptin, including details on side-effects, breast cancer, treatment, therapy.

Volume 2 (2005), Issue 7 (July)

1. In vitro characterization of a bivalent anti-HER-2 affibody with potential for radionuclide-based diagnostics.
   Cancer Biother Radiopharm, 20(3): 239-48. [Abstract] [Full-text]
2. The Cardiotoxicology of Anthracycline Chemotherapeutics: TRANSLATING MOLECULAR MECHANISM INTO PREVENTATIVE MEDICINE.
   Mol Interv, 5(3): 163-71. [Abstract] [Full-text]
3. Randomized phase II trial of the efficacy and safety of trastuzumab combined with docetaxel in patients with human epidermal growth factor receptor 2-positive metastatic breast cancer administered as first-line treatment: the M77001 study group.
   J Clin Oncol, 23(19): 4265-74. [Abstract] [Full-text]
4. Trastuzumab-mediated antibody-dependent cellular cytotoxicity against esophageal squamous cell carcinoma.
   Clin Cancer Res, 11(13): 4898-904. [Abstract] [Full-text]
5. Radiobromination of humanized anti-HER2 monoclonal antibody trastuzumab using N-succinimidyl 5-bromo-3-pyridinecarboxylate, a potential label for immunoPET.
   Nucl Med Biol, 32(6): 613-22. [Abstract] [Full-text]
6. Methods for isolating circulating epithelial cells and criteria for their classification as carcinoma cells.
   Cytotherapy, 7(2): 171-85. [Abstract] [Full-text]
7. Central nervous system metastases in breast cancer patients administered trastuzumab.
   Cancer Treat Rev, 31(4): 312-8. [Abstract] [Full-text]
8. Antitumoral actions of the anti-obesity drug orlistat (XenicalTM) in breast cancer cells: blockade of cell cycle progression, promotion of apoptotic cell death and PEA3-mediated transcriptional repression of Her2/neu (erbB-2) oncogene.
   Ann Oncol, 16(8): 1253-67. [Abstract] [Full-text]
9. HER2 signaling downregulation by trastuzumab and suppression of the PI3K/Akt pathway: an unexpected effect on TRAIL-induced apoptosis.
   FEBS Lett, 579(19): 4149-58. [Abstract] [Full-text]
10. Quantitative analysis of the farnesyl transferase inhibitor lonafarnib (Sarasartrade mark, SCH66336) in human plasma using high-performance liquid chromatography coupled with tandem mass spectrometry.
    Rapid Commun Mass Spectrom, 19(15): 2187-92. [Abstract] [Full-text]
11. Population pharmacokinetics of trastuzumab in patients with HER2+ metastatic breast cancer.
    Cancer Chemother Pharmacol, 56(4): 361-9. [Abstract] [Full-text]
12. ErbB2 activity is required for airway epithelial repair following neutrophil elastase exposure.
    FASEB J, 19(10): 1374-6. [Abstract] [Full-text]
13. Cellular uptake of radioiodine delivered by trastuzumab can be modified by the addition of epidermal growth factor.
    Eur J Nucl Med Mol Imaging, 32(7): 771-7. [Abstract] [Full-text]

© 2004-2008 Herceptin Research Today. All Rights Reserved.